Human Absorption Study of Liposomal Glucosamine Supplements
Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This study is a single-center, self-controlled crossover human trial designed to evaluate the differences in blood concentration changes and bioavailability following a single oral dose of glucosamine supplements.
Healthy adult participants aged 18 years and older will be enrolled. Each participant will complete four study sessions, with a minimum washout period of 7 days between sessions. On each study day, venous blood samples will be collected prior to test product administration (0 minutes) to assess glucosamine levels, complete blood count, blood lipids, blood glucose, and liver and kidney function indicators.
After baseline blood collection, a standardized breakfast will be provided and consumed within 10 minutes, followed by administration of the test product. Venous blood samples will then be collected at 0.5, 1, 2, 4, 8, and 24 hours post-intake to measure glucosamine concentrations. Lunch will be provided after the 4-hour blood draw, and dinner will be provided after the 8-hour blood draw. Identical meals will be provided on four study sessions.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Tong-Lin Wu
- Telefonnummer: +886 02-87977811
- E-mail: Tony.Wu@tci-bio.com
Undersøgelse Kontakt Backup
- Navn: Ping Lin
- Telefonnummer: +886 02-87977811
- E-mail: candice.lin@tci-bio.com
Studiesteder
-
-
-
Taipei, Taiwan, 114
- Rekruttering
- TCI Co., Ltd
-
Kontakt:
- Ping Lin
- Telefonnummer: +886 02-8797-7811
- E-mail: candice.lin@tci-bio.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures.
Exclusion Criteria:
- Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device.
- Employees of TCI Co., Ltd. and their family members.
- Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days.
- Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems/fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history.
- Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery.
- Individuals who have experienced acute gastroenteritis within 2 weeks prior to study initiation.
- Individuals with a history of allergy to any ingredient in the investigational products. The investigational products contain shrimp- and soy-derived ingredients.
- Vegetarians, as the glucosamine used in this study is derived from shrimp.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: High-Emulsified Liposomal Glucosamine Liquid
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
The formulation primarily consists of glucosamine HCl, a high proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
Andre navne:
|
|
Eksperimentel: Low-Emulsified Liposomal Glucosamine Liquid
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
The formulation primarily consists of glucosamine HCl, a low proportion of soy lecithin, and gum arabic, and is processed using the patented Double Nutri Liposomal technology.
Andre navne:
|
|
Aktiv komparator: Glucosamine Liquid without Liposomal
One sachet will be administered per dose, with each sachet containing 1,500 mg of glucosamine. |
The formulation primarily consists of glucosamine HCl and is not processed using the patented Double Nutri Liposomal technology. |
|
Aktiv komparator: Glucosamine tablet without Liposomal
Three tablets will be administered per dose, with each tablet containing 500 mg of glucosamine. |
The tablet formulation primarily consists of glucosamine HCl and is not processed using liposomal technology. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma glucosamine level (ng/mL)
Tidsramme: at 24 hours after taking test sample
|
Plasma glucosamine levels will be measured at fasting and at 0.5, 1, 2, 4, 8, and 24 hours post-intake. |
at 24 hours after taking test sample
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Tong-Lin Wu, TCI Co., Ltd.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 26-088-A
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .